Cargando…
PPARs as determinants of the estrogen receptor lineage: use of synthetic lethality for the treatment of estrogen receptor-negative breast cancer
THE DILEMMA: Estrogen receptora-negative (ER-) breast cancer lacks a specific critical target to control tumor progression. THE OBJECTIVE: To identify mechanisms that enable increased expression of the ER+ lineage in an otherwise ER- breast cancer. PREFACE: The nuclear receptor superfamily members P...
Autores principales: | Glazer, Robert I., Kopelovich, Levy |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5584135/ https://www.ncbi.nlm.nih.gov/pubmed/28881566 http://dx.doi.org/10.18632/oncotarget.17302 |
Ejemplares similares
-
Drug-Targeted Inhibition of Peroxisome Proliferator-Activated Receptorγ Enhances the Chemopreventive Effect of Anti-Estrogen
por: Yuan, Hongyan, et al.
Publicado: (2012) -
Erratum: Drug-Targeted Inhibition of Peroxisome Proliferator-Activated Receptor-gamma Enhances the Chemopreventive Effect of Anti-Estrogen Therapy
por: Yuan, Hongyan, et al.
Publicado: (2018) -
GATA3 and MDM2 are synthetic lethal in estrogen receptor-positive breast cancers
por: Bianco, Gaia, et al.
Publicado: (2022) -
Peering into the Brain’s Estrogen Receptors: PET Tracers for Visualization of Nuclear and Extranuclear Estrogen Receptors in Brain Disorders
por: Arjmand, Shokouh, et al.
Publicado: (2023) -
Estrogen receptor and aryl hydrocarbon receptor signaling pathways
por: Matthews, Jason, et al.
Publicado: (2006)